Curcumin and Cinnamaldehyde as PTP1B Inhibitors With Antidiabetic and Anticancer Potential

Anticancer Res. 2019 Feb;39(2):745-749. doi: 10.21873/anticanres.13171.

Abstract

Background/aim: Protein tyrosine phosphatase (PTP1B) is a potential target for the treatment of type 2 diabetes and cancer. Curcumin and cinnamaldehyde have been previously reported to have antidiabetic and anticancer potentials. The aim of this study was to investigate the effect of curcumin in comparison to cinnamaldehyde on the enzymatic activity of PTP1B and the viability of MCF-7 cancer cells.

Materials and methods: Enzymatic activity and cell viability assays were utilized. Experiments were performed using the breast cancer MCF-7 cell line.

Results: Curcumin and cinnamaldehyde decreased the activity of PTP1B, and had inhibitory effects on the viability of MCF-7 cancer cells. Curcumin had a significantly higher inhibitory effect than cinnamaldehyde.

Conclusion: Curcumin can be considered a potential agent for the treatment of type-2 diabetes or cancer.

Keywords: PTP1B phosphatase; Type 2 diabetes; cancer; cinnamaldehyde; curcumin; obesity.

MeSH terms

  • Acrolein / analogs & derivatives*
  • Acrolein / chemistry
  • Acrolein / pharmacology
  • Antineoplastic Agents / pharmacology*
  • Breast Neoplasms / drug therapy*
  • Cell Survival / drug effects
  • Curcumin / chemistry
  • Curcumin / pharmacology*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Drug Screening Assays, Antitumor
  • Female
  • Humans
  • Hypoglycemic Agents / pharmacology*
  • MCF-7 Cells
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1 / antagonists & inhibitors*

Substances

  • Antineoplastic Agents
  • Hypoglycemic Agents
  • Acrolein
  • PTPN1 protein, human
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1
  • Curcumin
  • cinnamaldehyde